PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics is advancing its investigational drug PYC-003 into human trials, aiming to address the unmet needs of patients with Autosomal Dominant Polycystic Kidney Disease. Recent pre-clinical studies show promising results, with effective gene expression control and a favorable safety profile. The trials are expected to start in early 2025, marking a significant step for the company in tackling genetic diseases.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
